Doreen Wood serves as the Vice President Program Lead at ITM Isotope Technologies Munich SE, where she spearheads the late-stage development of innovative radiopharmaceutical therapies targeting oncology indications. With a robust background in both big pharma and biotechnology, Doreen has successfully directed complex international drug...
Doreen Wood serves as the Vice President Program Lead at ITM Isotope Technologies Munich SE, where she spearheads the late-stage development of innovative radiopharmaceutical therapies targeting oncology indications. With a robust background in both big pharma and biotechnology, Doreen has successfully directed complex international drug development programs, guiding them through the intricate pathways to market approval across Europe, the United States, and Asia. Her expertise lies in designing and executing comprehensive development strategies that align seamlessly with overarching business goals, ensuring that each project not only meets regulatory standards but also addresses critical patient needs.
A key aspect of Doreen’s role involves leading cross-functional, multi-cultural, and virtual teams, fostering collaboration among diverse stakeholders to drive projects forward. Her ability to optimize communications and enhance effectiveness with senior management has been instrumental in navigating the challenges of drug development. Doreen’s proficiency in project management, risk assessment, and due diligence ensures that potential hurdles are identified and mitigated early in the process, allowing for smoother transitions from concept to clinical trials and ultimately to market launch.
In addition to her leadership in program development, Doreen's deep understanding of endocrinology and biologics positions her as a vital contributor to the advancement of therapeutic solutions in oncology. Her commitment to problem-solving and her strategic approach to licensing further underscore her capability to bring innovative therapies to fruition, making her a key player in the evolving landscape of radiopharmaceuticals. Through her work at ITM, Doreen is not only advancing the field but also significantly impacting patient outcomes in oncology care.
